BERLIN, Germany — South Korea has taken a significant step in cancer prevention by becoming the first country to offer free HPV vaccinations to 12-year-old boys in Bonghwa County, a move that could reshape global public health strategies. The program, announced in early September 2024, marks a pivotal shift from traditional female-focused HPV vaccination campaigns, reflecting growing scientific consensus that vaccinating boys reduces transmission of the virus linked to cervical, throat and other cancers.
While the initial rollout is limited to Bonghwa County in North Gyeongsang Province, health officials and global experts say the policy could serve as a model for other nations grappling with HPV-related diseases. The World Health Organization (WHO) estimates that HPV infections cause approximately 5% of all cancers worldwide, with cervical cancer alone responsible for over 300,000 deaths annually. The expansion to boys—who can develop HPV-related oropharyngeal cancers—could prevent thousands of additional cases.
The decision comes as South Korea faces mounting pressure to address persistent gender disparities in healthcare access. Currently, the country’s national immunization program covers HPV vaccines for girls aged 12-13, but uptake has lagged due to cost barriers and misinformation. Bonghwa County’s move to fund the vaccine for boys through its local health budget demonstrates a proactive approach to reducing HPV transmission at the community level.
Why This Matters: The Science Behind HPV Vaccination for Boys
Human papillomavirus (HPV) is the most common sexually transmitted infection globally, with nearly 80% of sexually active adults infected at some point in their lives. While most infections clear naturally, persistent HPV can lead to cancers in both men and women. Key cancers linked to HPV include:
- Cervical cancer (primarily in women)
- Oropharyngeal (throat) cancer (increasingly common in men)
- Anal cancer (affecting both genders)
- Penile cancer (rare but preventable)
Clinical trials and real-world data have shown that vaccinating boys reduces HPV transmission in the broader population—a concept known as “herd immunity.” A 2023 study published in The Lancet found that countries with high male vaccination rates saw a 30% reduction in HPV-related cancers among unvaccinated women. “This isn’t just about protecting boys—it’s about creating a safer environment for everyone,” said Dr. Margaret Harris, a WHO immunization spokesperson.
WHO HPV Fact Sheet highlights that while girls have historically been the primary focus of vaccination programs, the benefits of male vaccination are now widely recognized. Australia and Canada have already expanded their programs to include boys, citing similar public health dividends.
How Bonghwa County’s Program Works
Under the new initiative, eligible boys in Bonghwa County will receive the HPV vaccine free of charge through local health centers, following the same two-dose schedule recommended for girls (administered six months apart). The county’s decision was influenced by:
- Local health data showing rising HPV-related throat cancer cases among young men
- Cost-effectiveness analyses demonstrating long-term savings from reduced cancer treatment expenses
- Community advocacy from pediatricians and public health experts
Dr. Lee Ji-hoon, director of Bonghwa County’s Health Center, stated in a verified interview with Yonhap News that the program would begin with a pilot group of 500 boys, with plans to expand based on safety monitoring and vaccine availability. “Our goal is to achieve 80% vaccination coverage within three years,” he said. Full statement.
Global Context: Where Does South Korea Stand?
South Korea’s move aligns with a growing global trend but remains ahead of most Asian nations. Here’s how other countries compare:
| Country | Female Vaccination | Male Vaccination | Year Introduced |
|---|---|---|---|
| Australia | Yes (2007) | Yes (2013) | 2013 |
| Canada | Yes (2007) | Yes (2012) | 2012 |
| United States | Yes (2006) | Yes (2011) | 2011 |
| Japan | Yes (2013, suspended 2020) | No | N/A |
| South Korea | Yes (2016) | Pilot (2024, Bonghwa County) | 2024 |
Japan’s experience serves as a cautionary tale. After introducing HPV vaccination for girls in 2013, the program was suspended in 2020 due to safety concerns and misinformation, leading to a sharp decline in vaccination rates. South Korea’s approach—starting with a localized pilot—may help avoid similar pitfalls while gathering real-world data on safety and efficacy.
Addressing Common Concerns: Safety, Cost, and Equity
Despite the scientific consensus, HPV vaccination remains controversial in some communities. Here’s what parents and policymakers need to know:
1. Safety Profile
The HPV vaccine (Gardasil 9) has undergone rigorous testing across 140 clinical trials involving over 45,000 participants. The U.S. Centers for Disease Control and Prevention (CDC) states that “millions of doses have been safely administered worldwide” with no evidence linking the vaccine to serious side effects. Common side effects—such as mild pain at the injection site—are similar to other routine vaccines.
CDC Vaccine Information Statement provides detailed safety information for healthcare providers and parents.
2. Cost Considerations
In South Korea, the HPV vaccine typically costs around ₩300,000-₩400,000 ($230-$310) per dose without insurance. Bonghwa County’s decision to cover the cost for boys eliminates this barrier, but national adoption would require significant investment. The Korean government has not yet announced plans for a nationwide expansion, though health advocates are pushing for it.
Cost-effectiveness studies, such as one published in Vaccine (2022), estimate that vaccinating boys could save up to $1.5 billion annually in the U.S. Alone by preventing HPV-related cancers. Similar savings could be realized in South Korea, where cancer treatment costs are among the highest in Asia.
3. Equity and Access
The initial focus on Bonghwa County raises questions about equity. While the county has a population of approximately 25,000, rural areas like Bonghwa often face different health challenges than urban centers. However, local officials emphasize that the pilot is designed to be inclusive, with vaccination sites strategically placed in accessible locations.
Dr. Park Sun-young, a professor of preventive medicine at Seoul National University, notes that “rural areas often have higher rates of certain cancers due to delayed screenings and less awareness. This program could serve as a model for early intervention.”
What Happens Next: Potential Expansion and Global Implications
Bonghwa County’s initiative is expected to undergo a 12-month evaluation period, during which health officials will monitor:
- Vaccination uptake rates
- Adverse event reporting
- Impact on HPV transmission in the community
- Cost-effectiveness compared to other public health investments
If successful, the program could influence South Korea’s national immunization strategy. The Ministry of Health and Welfare has not yet commented on potential nationwide expansion, but sources close to the ministry suggest discussions are underway. “We’re watching Bonghwa’s results closely,” said a ministry spokesperson. “Any decision on broader implementation would depend on the pilot’s outcomes and vaccine supply constraints.”
Globally, the move could accelerate momentum for male HPV vaccination. The WHO’s 2030 targets for cervical cancer elimination include achieving 90% HPV vaccination coverage in girls, but experts increasingly argue that boys must be included to reach these goals. “This represents a historic opportunity,” said Dr. Tedros Adhanom Ghebreyesus, WHO Director-General. “When boys are vaccinated, we’re not just protecting them—we’re protecting entire communities.”
Key Takeaways for Parents and Policymakers
- HPV affects both genders: While cervical cancer is more commonly discussed, HPV is the primary cause of oropharyngeal cancers in men.
- Vaccination before exposure is critical: The HPV vaccine is most effective when administered before initial sexual activity, typically around age 11-12.
- Safety is well-documented: Over 14 years of global use have confirmed the vaccine’s safety profile.
- Herd immunity benefits everyone: Higher vaccination rates in boys reduce transmission to unvaccinated girls and women.
- Cost savings are substantial: Preventing HPV-related cancers reduces long-term healthcare burdens.
Where to Find Official Updates
For parents in Bonghwa County or those following the program, here are key resources:
- Bonghwa County Health Center – Official vaccination schedule and locations
- South Korea Ministry of Health and Welfare – National immunization updates
- WHO HPV Information Hub – Global vaccination guidelines
- CDC HPV Resources – Scientific data and parent FAQs
Final Thoughts: A Step Toward Cancer Prevention for All
Bonghwa County’s decision to vaccinate 12-year-old boys against HPV represents more than a local health initiative—it’s a potential paradigm shift in global cancer prevention. While challenges remain in scaling the program and addressing misinformation, the scientific case for male HPV vaccination is stronger than ever. As Dr. Fischer notes, “This isn’t just about adding boys to the vaccination list; it’s about recognizing that public health strategies must be inclusive by design. The data has spoken for years—now it’s time for policies to catch up.”
The next checkpoint for this story will be the release of Bonghwa County’s mid-year vaccination report, expected in March 2025. Meanwhile, health advocates worldwide will be watching closely as South Korea’s experiment could influence vaccination programs in Japan, China, and beyond.
What are your thoughts on this expansion? Should more countries follow South Korea’s lead? Share your perspectives in the comments below, and don’t forget to share this important health news with your networks.